Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

🩺 Protocol Summary

Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).

Primary Research Facility: University of Illinois Chicago, Sickle Cell Center (Chicago, Illinois)

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

Diagnosed with, undergoing evaluation for, or seeking treatment related to Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)?

🔍 Study Population / Focus Area (Source: Protocol Primary Condition)

Aged between 18 Years and 60 Years?

🔍 Protocol Specified Age Range: 18 Years to 60 Years

Able to attend required clinic visits at University of Illinois Chicago, Sickle Cell Center (Chicago, Illinois)?

🔍 Logistical Requirement: Site at University of Illinois Chicago, Sickle Cell Center

📍 Primary Site Map

Site: University of Illinois Chicago, Sickle Cell Center — Chicago, Illinois

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.